Loading
Software that reads digitised biopsy slides to detect cancer, grade it, and score biomarkers such as HER2, PD-L1 and Ki-67 more consistently than the eye alone.
Deep-learning models trained on whole-slide images now detect prostate cancer in biopsies (Paige Prostate, the first FDA-authorised AI pathology tool, 2021), assist Gleason grading, count mitoses, and quantify immunohistochemistry such as HER2, PD-L1 and Ki-67, where pathologist agreement is known to be poor at the decision thresholds. Newer models infer molecular states, such as microsatellite instability, directly from routine H&E slides.
Convolutional or transformer networks trained on annotated whole-slide images produce per-region probabilities that are aggregated into detections, grades or scores presented to the pathologist.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Query for this technology: (TITLE:"AI scoring of biomarkers and grade on pathology slides" OR ABSTRACT:"AI scoring of biomarkers and grade on pathology slides") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AI scoring of biomarkers and grade on pathology slides, not a curated reading list.
Shares Vicinity Bio, Digital pathology & AI.
Shares Digital pathology & AI, HER2-positive breast cancer, Prostate cancer.
Shares Digital pathology & AI, Prostate cancer.
Shares Digital pathology & AI, Prostate cancer.
Shares Vicinity Bio, Digital pathology & AI.
Shares Digital pathology & AI, Prostate cancer.
Shares Digital pathology & AI, Prostate cancer.
Commercial and regulated products that serve this technology. Each card says what is behind it: a regulator's database, the literature, a public body's list, or only the company's own words. Listing is not endorsement, and a clearance is a regulatory fact, not a clinical one.
An algorithm that flags areas suspicious for prostate cancer on a scanned biopsy slide, the first such pathology algorithm authorised in the United States.
A platform for training and running deep-learning models on whole-slide images, sold to laboratories that want to build their own scoring algorithms.
Quantitative image analysis for stained tissue sections, used to score markers such as HER2, Ki-67 and PD-L1 rather than eyeballing them.
An algorithm that grades prostate biopsy slides, reporting Gleason patterns and tumour extent for a pathologist to confirm.
A digital pathology case management and image analysis platform used in diagnostic laboratories and in research.
Algorithms that score immunohistochemistry on breast slides, sold to run inside the laboratory's existing viewer.